NIH Funds NCI Research for Neuroblastoma T-Cell Therapy IND Application
What happened
The National Cancer Institute received a Phase II grant of $2,058,885 from the National Institutes of Health. This funding supports the advancement of ET501, an investigational T-cell therapy designed for children with high-risk neuroblastoma, toward an Investigational New Drug application to the U.S. Food and Drug Administration.
From prnewswire.com
Why it matters
The award supports the clinical-stage research of a gene and cell therapy aimed at treating a pediatric cancer. The funding helps the therapy progress through the necessary steps required for regulatory review by the U.S. Food and Drug Administration.
From prnewswire.com
Who's involved
- National Institutes of HealthGovernment organization that awarded the Phase II research grant.
- National Cancer InstituteSubsidiary of the National Institutes of Health that conducted the research.
- FDARegulatory agency to which the research is being prepared for submission.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- National Cancer InstituteSpeculative
The National Cancer Institute could see increased research costs covered by the grant funding.
Keep exploring
The entities involved
- FDA
-
National Institutes of Health
government organization in Shah Alam, Malaysia
-
National Cancer Institute
public hospital in Milan dedicated to cancer care
Related events
- The National Institutes of Health awarded funding for research and health programs to the University of Nebraska Medical Center.
- NIH provided federal grant funding to UF for research.
- Ohio covers FDA-approved uses of drugs, supported by scientific basis from the National Institutes of Health.
- NIH, NSF, and NASA provided active funding to University of Hawaii research on October 29, 2026.
- FDA approval supports NDA submission in Aurora.